首页> 外国专利> Injectable liquid formulation for prolonged release of interleukin, e.g. for immunomodulation, based on aqueous colloidal suspension of water-soluble, biodegradable polymer forming gelled depot on injection

Injectable liquid formulation for prolonged release of interleukin, e.g. for immunomodulation, based on aqueous colloidal suspension of water-soluble, biodegradable polymer forming gelled depot on injection

机译:用于延长白介素释放的可注射液体制剂,例如用于免疫调节,基于水溶性,可生物降解的聚合物的水性胶体悬浮液,可在注射时形成胶凝储库

摘要

A liquid pharmaceutical formulation (I) for prolonged release of interleukin(s) (IL) comprises a low viscosity aqueous colloidal suspension of submicron particles of water-soluble, biodegradable polymers (II) carrying hydrophobic groups, non-covalently associated with IL(s) and optionally other active agent(s), where on parenteral injection (I) forms a gelled depot for prolonging the duration of active agent release to more than 24 hours. A liquid pharmaceutical formulation (I) for prolonged release of interleukin(s) (IL) comprises a low viscosity aqueous colloidal suspension (with water as dispersion medium) based on submicron particles (SMP's) of water-soluble, biodegradable polymers (II) carrying hydrophobic groups (HG's), non-covalently associated with IL(s) and optionally other active agent(s). On parenteral injection, (I) forms a gelled depot in vivo (at least partially due to physiological proteins), controlling and prolonging the duration of active agent release to more than 24 hours. (I) is liquid under the injection conditions; at physiological temperature and/or pH; and/or in presence of physiological electrolytes at physiological concentrations and/or surfactant(s). Independent claims are included for: (1) a variant of (I) as described above, where the duration of release of active agents is not restricted but the concentration of (II) is sufficiently high to form a gelled depot in vivo in presence of protein(s) after parenteral injection; (2) novel derived products (preferably in powder or gel form), consisting of SMP's formed by non-covalent association of (II) and active agents as above and obtained from (I); and (3) methods of preparation of (I). ACTIVITY : Antiinflammatory; immunomodulator. MECHANISM OF ACTION : T-Lymphocyte activator; T-lymphocyte proliferation profieration inducer.
机译:用于延长白介素(IL)释放的液体药物制剂(I)包含具有疏水基团的水溶性,可生物降解的聚合物(II)的亚微米颗粒的低粘度水性胶体悬浮液,该疏水基团与IL非共价结合)和任选的其他活性剂,其中在肠胃外注射(I)时会形成凝胶状长效制剂,以将活性剂的释放时间延长至24小时以上。用于延长白介素(IL)释放的液体药物制剂(I)包含基于水溶性,可生物降解聚合物(II)的亚微米颗粒(SMP)的低粘度水性胶体悬浮液(以水为分散介质)与IL和非必要的其他活性剂非共价结合的疏水基团(HG)。肠胃外注射时,(I)在体内形成凝胶化的贮库(至少部分归因于生理蛋白),将活性剂的释放时间控制和延长至超过24小时。 (I)在注射条件下为液体;在生理温度和/或pH下;和/或在生理浓度和/或表面活性剂的生理电解质存在下。包括以下方面的独立权利要求:(1)如上所述的(I)的变体,其中活性剂的释放持续时间不受限制,但(II)的浓度足够高,可以在存在以下情况下在体内形成凝胶贮库肠胃外注射后的蛋白质; (2)新颖的衍生产物(优选为粉末或凝胶形式),其由通过(II)与上述活性剂的非共价缔合形成并从(I)获得的SMP组成; (3)(I)的制备方法。活性:抗炎;免疫调节剂。作用机理:T淋巴细胞活化剂; T淋巴细胞增殖促进剂。

著录项

  • 公开/公告号FR2862535A1

    专利类型

  • 公开/公告日2005-05-27

    原文格式PDF

  • 申请/专利权人 FLAMEL TECHNOLOGIES;

    申请/专利号FR20030050888

  • 发明设计人 BIGNON SOPHIE;SOULA OLIVIER;MEYRUEIX REMI;

    申请日2003-11-21

  • 分类号A61K9/08;A61K9/14;A61K38/20;

  • 国家 FR

  • 入库时间 2022-08-21 21:58:19

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号